Tracking patient response to DMARD therapy has the potential to improve remission, but multiple barriers must be overcome ...

The research has been published in the International Journal of Clinical Biochemistry and Research ... Conditions such as ...

Investing in Cabaletta Bio for potential high returns on innovative CAR-T therapies despite volatility and risk. Click here ...

Dr. Gary Deng of the Integrative Medicine Service helps separate the hype from the proven health benefits of mushroom ...

"We are honored to welcome Alison to the Artiva Board of Directors. Her decades of executive experience in manufacturing and ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

New guideline by ASA: Preventing a first stroke may be possible with screening, lifestyle changesThe "2024 Guideline for the ...

The "2024 Guideline for the Primary Prevention of Stroke" replaces the 2014 version and is a resource for clinicians in implementing a variety of prevention strategies for individuals with no ...

Roivant's high valuation is justified, with a strong cash position, promising drug pipeline, and strategic partnerships ...

Research has shown that more than 50% of adults and most children with lupus have elevated interferon levels, according to the Lupus Research Alliance, which said the TULIP-2 data is “welcome ...

There are no significant differences in outcomes post-AMI in patients with systemic lupus erythematosus vs the general population.

Otsuka Pharmaceutical’s kidney disease drug has hit the primary endpoint of a phase 3 trial by demonstrating in an interim ...